Overview

A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To prove non-inferiority of MR4 to Prograf by evaluating the efficacy and safety of Prograf and MR4 in new kidney transplant recipients
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma Korea, Inc.
Treatments:
Tacrolimus